Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00761787 · ClinicalTrials.gov registry record

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

A clinical trial of Heart Disease and Graft Rejection, sponsored by XDx.

Completed
Registry status
800
Enrollment target
17
Study locations

NCT00761787: Completed study of Heart Disease and Graft Rejection, sponsored by XDx.

NCT00761787 is a study of Heart Disease and Graft Rejection that has completed, run by XDx. The registered enrollment target is 800 participants, below the 2,021-participant average among 31 other Heart Disease trials with a reported enrollment target (60% lower). The trial reports 17 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00761787, a study of Heart Disease and Graft Rejection, has completed, sponsored by XDx.

COMPLETED
Registry status
800 participants
Enrollment target
17
Study locations

Study Summary

The Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study is designed to provide independent evidence of the clinical performance of the non-invasive AlloMap test. Sensitive detection of cardiac allograft rejection and dysfunction is the basis for successful recipient management. The CARGO II Study will assess the correlation between the presence or absence of acute cellular rejection as determined by examination of endomyocardial biopsy specimens with results from the AlloMap Test. Of 17 participating transplant centers, 4 are in North America and 13 are in Europe.

Study Locations (17)

Minnesota

  • University of Minnesota - Minneapolis

New York

  • Columbia University Medical Center - New York

Texas

  • Texas Heart Institute - Houston

Innsbruck

  • Medizinische Universität Innsbruck, Klinische Abteilung für Herzchirurgie - Anichstrasse 35

Vienna

  • Medical University of Vienna (Medizinische Universität Wien) - Währinger Gürtel 18-20

Leuven

  • UZ Gasthuisberg - Herestraat 49

Ontario

  • Toronto General Hospital - Toronto

Paris

  • Hospital La Pitie - 47 Bd de L

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2005-05
Est. Completion 2009-02
XDx

3 total trials

What the finished NCT00761787 record still lists

NCT00761787 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 2,021-participant average among 31 other Heart Disease trials with a reported enrollment target (60% lower).

The record links to 2 conditions, with Heart Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00761787 lists 17 locations in 17 states (Minnesota, New York, Texas).

Frequently Asked Questions

What is clinical trial NCT00761787 about?

NCT00761787 is a clinical study titled "Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY". The Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study is designed to provide independent evidence of the clinical performance of the non-invasive AlloMap test. Sensitive detection of cardiac allograft rejection and dysfunction is the basis for successful recipient management...

What is the current status of trial NCT00761787?

This trial is currently completed. The enrollment target is 800 participants. The study started on 2005-05. Estimated completion is 2009-02.

What conditions does trial NCT00761787 study?

This clinical trial studies the following conditions: Heart Disease, Graft Rejection.

Who is sponsoring clinical trial NCT00761787?

This trial is sponsored by XDx, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00761787 being conducted?

This trial has 17 study locations across Minnesota, New York, Texas, Innsbruck, Vienna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00761787's enrollment target sits among peer trials

800 5th of 31 higher than 27 of 31 other Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00761787, the US trial registry maintained by the National Library of Medicine. NCT00761787 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.